Discovering new drugs with Darwin
Our body must constantly defend itself against bacteria and viruses. It generates millions of different antibodies, which are selected to recognise the enemy and trigger the best possible immune response. Scientists use these antibodies to for therapeutic purposes to target proteins and disrupt their harmful. However, identifying the small molecules that will form the basis of the drug is a long and tedious process. (Source: World Pharma News)
Source: World Pharma News - December 7, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche completed the repurchase of Roche shares from Novartis
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary General Meeting of Roche Holding Ltd passed the resolutions required for the repurchase and the capital reduction on 26 November 2021. (Source: World Pharma News)
Source: World Pharma News - December 6, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Rapid test identifies antibody effectiveness against COVID-19 variants
Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person’s neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant. This test could potentially tell doctors how protected a patient is from new variants and those currently circulating in a community or, conversely, which monoclonal antibodies to treat a COVID-19 patient. (Source: World Pharma News)
Source: World Pharma News - December 6, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
GlaxoSmithKline plc and the University of Oxford announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. The new Institute, which will be based at the University of Oxford, aims to improve the success and speed of research and development of new medicines, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning. (Source: World Pharma News)
Source: World Pharma News - December 3, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Which COVID-19 vaccine works better?
In the first head-to-head comparison of the effectiveness of the Pfizer-BioNTech and Moderna COVID-19 vaccines, researchers examined the electronic health records of veterans who had received each vaccine. Both vaccines were highly effective in preventing COVID-19 outcomes such as documented infection, hospitalization, and death. (Source: World Pharma News)
Source: World Pharma News - December 2, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AWS helps Pfizer accelerate drug development and clinical manufacturing
Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, (Source: World Pharma News)
Source: World Pharma News - December 2, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Delaying second dose of mRNA COVID-19 vaccine produces stronger immune response
The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF). (Source: World Pharma News)
Source: World Pharma News - December 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
GlaxoSmithKline (GSK) plc today launched Target the Future, an international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community. The programme will provide education on progress in the field of multiple myeloma, identify key challenges the community faces, and facilitate solutions to help create a better future for patients, their caregivers and loved ones. (Source: World Pharma News)
Source: World Pharma News - December 1, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and behaviors associated with a higher risk of infection with SARS-CoV-2. (Source: World Pharma News)
Source: World Pharma News - November 30, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

WHO update on Omicron
On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes. (Source: World Pharma News)
Source: World Pharma News - November 29, 2021 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments. Owkin, an artificial intelligence (AI) and precision medicine company, builds best-in-class predictive biomedical AI models and robust data sets. (Source: World Pharma News)
Source: World Pharma News - November 26, 2021 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute. The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor. (Source: World Pharma News)
Source: World Pharma News - November 25, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform
The International Cancer Genome Consortium (ICGC) is further enabling cancer research worldwide by making a massive collection of cancer data available for analysis via Microsoft's Azure cloud computing platform. Providing secure, controlled access to ICGC genomic and clinical data on Azure will mitigate the need for researchers to obtain massive amounts of storage and computing power within their home institutions, meaning that more researchers will be able to use the data. (Source: World Pharma News)
Source: World Pharma News - November 24, 2021 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Aspirin is linked with increased risk of heart failure
Aspirin use is associated with a 26% raised risk of heart failure in people with at least one predisposing factor for the condition. That’s the finding of a study published today in ESC Heart Failure, a journal of the European Society of Cardiology (ESC). Predisposing factors included smoking, obesity, high blood pressure, high cholesterol, diabetes, and cardiovascular disease. (Source: World Pharma News)
Source: World Pharma News - November 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity
The population's immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity - previous antibody responses to other, harmless coronaviruses. (Source: World Pharma News)
Source: World Pharma News - November 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series. (Source: World Pharma News)
Source: World Pharma News - November 22, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in May 2021. (Source: World Pharma News)
Source: World Pharma News - November 19, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). If approved or authorized, PAXLOVID, which originated in Pfizer's laboratories, would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2. (Source: World Pharma News)
Source: World Pharma News - November 18, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai, ASC Therapeutics and Within3
9 December, 2021. 10AM EST, 3PM GMT, 4PM CET. Virtual Event. Medical affairs teams are challenged by rising costs and accelerated timelines - and hampered by inefficiency throughout the insight gathering process. These breakdowns occur before a single insight is collected: by engaging with the wrong KOLs, medical affairs won't access the right strategic insights while wasting time and effort. (Source: World Pharma News)
Source: World Pharma News - November 18, 2021 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Modernise your Medical Affairs Insight Management with ViiV Healthcare, Eisai and Within3
9 December, 2021. 10AM EST, 3PM GMT, 4PM CET. Virtual Event. Medical affairs teams are challenged by rising costs and accelerated timelines - and hampered by inefficiency throughout the insight gathering process. These breakdowns occur before a single insight is collected: by engaging with the wrong KOLs, medical affairs won't access the right strategic insights while wasting time and effort. (Source: World Pharma News)
Source: World Pharma News - November 18, 2021 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Repurposing a familiar drug for COVID-19
For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2. (Source: World Pharma News)
Source: World Pharma News - November 17, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Scientists identify new types of a blood cancer and potential targeted treatments
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted treatments based on the findings, as reported in Science Advances in November. (Source: World Pharma News)
Source: World Pharma News - November 17, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Two billion doses of AstraZeneca ’s COVID-19 vaccine supplied to countries across the world
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility. (Source: World Pharma News)
Source: World Pharma News - November 16, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Coffee and tea drinking may be associated with reduced rates of stroke and dementia
Drinking coffee or tea may be associated with a lower risk of stroke and dementia, according to a study of healthy individuals aged 50-74 publishing November 16th in the open-access journal PLOS Medicine. Drinking coffee was also associated with a lower risk of post-stroke dementia. (Source: World Pharma News)
Source: World Pharma News - November 16, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase III trial, which achieved its primary endpoint, demonstrating intramuscular (IM) administration of sotrovimab was non-inferior to intravenous (IV) administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalised adults and adolescents (12 years of age and older). (Source: World Pharma News)
Source: World Pharma News - November 15, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. (Source: World Pharma News)
Source: World Pharma News - November 15, 2021 Category: Pharmaceuticals Tags: Featured Merck Business and Industry Source Type: news

Johnson & Johnson COVID-19 vaccine named one of Time's Best Inventions of 2021
The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & Johnson received Emergency Use Authorization from the U.S. Food and Drug Administration in February, is being recognized in the Medical Care category alongside two other COVID-19 vaccines. (Source: World Pharma News)
Source: World Pharma News - November 12, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

'Dancing molecules' successfully repair severe spinal cord injuries
Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal cord injuries. In a new study, researchers administered a single injection to tissues surrounding the spinal cords of paralyzed mice. Just four weeks later, the animals regained the ability to walk. (Source: World Pharma News)
Source: World Pharma News - November 11, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the antibody combination, Ronapreve™ (casirivimab and imdevimab), for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of their disease becoming severe, and for preventing COVID-19 in people aged 12 years and older weighing at least 40 kilograms (pre- or post-exposure prophylaxis). (Source: World Pharma News)
Source: World Pharma News - November 11, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

New target for COVID-19 vaccines identified
Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, concludes new research carried out by UCL scientists. By designing vaccines that activate immune memory cells, known as T cells, to attack infected cells expressing this part of the virus’s internal machinery, it may be possible to eliminate SARS-CoV-2 at the very outset, thereby helping stop its spread. (Source: World Pharma News)
Source: World Pharma News - November 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

A target for potential cancer drugs may, in fact, worsen disease
In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2. Shp2 is a phosphotyrosine phosphatase; its job is to remove phosphates from protein tyrosine residues, aiding and abetting signal communications within cells. (Source: World Pharma News)
Source: World Pharma News - November 9, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Safety concerns raised for neuroblastoma candidate drug
St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Then researchers identified safety concerns with the experimental drug that have implications for current clinical trials in adults. The study appears today in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - November 9, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study offers insights on why the elderly are more susceptible to COVID-19
Among the populations most significantly affected by COVID-19 are the elderly and patients with preexisting medical conditions including diabetes, hypertension, obesity, metabolic syndrome, cardiovascular disease and chronic lung diseases like COPD and asthma. (Source: World Pharma News)
Source: World Pharma News - November 8, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis to sell its Roche stake in a bilateral transaction to Roche
Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. Vas Narasimhan, CEO of Novartis, said: "After more than 20 years as a shareholder of Roche, we concluded that now is the right time to monetize our investment. (Source: World Pharma News)
Source: World Pharma News - November 8, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase 2/3 EPIC-HR study
Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. (Source: World Pharma News)
Source: World Pharma News - November 5, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Finding a new purpose for old drugs: Researchers have found promising drugs for COVID-19
Treatment options for COVID-19 remain limited. Researchers at the University of Helsinki and the University of Eastern Finland first searched for suitable drug targets and repurposable drugs for these, leading to finding six candidate drugs that demonstrate antiviral effects against SARS-CoV-2. Understanding viral pathogenesis at the molecular level is critical in developing effective therapies for COVID-19. (Source: World Pharma News)
Source: World Pharma News - November 4, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novel drug liberates tumour vessels to aid cancer drug delivery
A therapeutic antibody developed by scientists at UCL has been shown to unblock and normalise blood vessels inside cancerous tumours, enabling the more effective delivery of targeted cancer treatments. The findings in mice, published in the journal MED, are the first to demonstrate that inhibiting the activity of LRG1, a protein produced in many tumorous tissues, liberates disorganised angiogenesis (blood vessel formation) - a leading cause of morbidity in numerous diseases including cancer. (Source: World Pharma News)
Source: World Pharma News - November 3, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abbott launches new initiative to drive diversity in medical research and improve care among under-represented populations
Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, education, and improving the clinical research infrastructure within the U.S. This effort builds on Abbott's commitment of engaging populations who have historically been under-represented in medical research and will improve health by increasing access to innovative treatment options available within the trials process and increasing insights around how different groups respond to new therapies. (Source: World Pharma News)
Source: World Pharma News - November 3, 2021 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

Researchers reveal a strategy for next-generation COVID-19 vaccines
A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells and that are more resistant to evolving viral strains. The team’s key criteria for antibodies generated by future vaccines are to target regions of the SARS-CoV-2 viral surface that are unlikely to mutate and share key features that the researchers found could block the virus from infecting human cells. (Source: World Pharma News)
Source: World Pharma News - November 2, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

A commonly found parasite could treat certain types of cancer
Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various types of tumours. The research, published today in the Journal for ImmunoTherapy Cancer, was carried out by experts from the University of Nottingham, Ningbo University and Shanxi Agricultural University in China. (Source: World Pharma News)
Source: World Pharma News - November 2, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cleveland Clinic launches first-of-its kind preventive breast cancer vaccine study
Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. This phase I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body's immune response. (Source: World Pharma News)
Source: World Pharma News - November 1, 2021 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Rice web server helps identify COVID-19 drug candidates
Rice University researchers have introduced an online portal to help researchers screen COVID-19 drug candidates that might attack specific proteins of the SARS-CoV-2 virus. Lydia Kavraki, a computer scientist at the George R. Brown School of Engineering, and her colleagues at the University of Houston, the University of Edinburgh, Scotland, and the Federal University of Ceará, Brazil, have posted a "user-friendly" web server offering scientists the chance to screen their drug candidates virtually in relation to known protein binding pockets on the SARS-CoV-2 virus. (Source: World Pharma News)
Source: World Pharma News - November 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
Today, the U.S. Food and Drug Administration authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age. The authorization was based on the FDA's thorough and transparent evaluation of the data that included input from independent advisory committee experts who overwhelmingly voted in favor of making the vaccine available to children in this age group. (Source: World Pharma News)
Source: World Pharma News - October 29, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Needle-free COVID-19 vaccine shows promise
A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed vaccine candidate with a ‘patch’. The University of Texas Hexapro vaccine candidate - delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP) - provided protection against COVID-19 disease with a single, pain-free 'click' from a pocket-sized applicator. (Source: World Pharma News)
Source: World Pharma News - October 29, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease. While there are approximately 7,000 rare diseases, only two heritable diseases currently have FDA-approved gene therapies. (Source: World Pharma News)
Source: World Pharma News - October 28, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040
ViiV Healthcare announced the release of Achieving health equity: a roadmap to eliminating disparities, a new report conducted by Economist Impact, a division of The Economist Group, that explores the opportunities that could be created by eliminating health disparities in the UK and US over the next 20 years, while charting a bold course for unified action. (Source: World Pharma News)
Source: World Pharma News - October 27, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

New computer modelling could boost drug discovery
Scientists from Queen's University Belfast have developed a computer-aided data tool that could improve treatment for a range of illnesses. The computer modelling tool will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects. (Source: World Pharma News)
Source: World Pharma News - October 27, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Horse hyperimmune antibody may help the fight against COVID-19
A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. Tests conducted in hamsters improved the animal clinical conditions. The neutralizing activity of the sera developed by the scientists has been proved to be high against the P.1 (Gamma) and P.2 variants. (Source: World Pharma News)
Source: World Pharma News - October 26, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news